SRTS - Sensus Healthcare, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
6.39
+0.10 (+1.59%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close6.29
Open6.34
Bid0.00 x 1200
Ask0.00 x 1400
Day's Range6.28 - 6.46
52 Week Range5.31 - 9.23
Volume30,574
Avg. Volume47,125
Market Cap104.827M
Beta (3Y Monthly)-0.47
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • PR Newswire11 hours ago

    Sensus Healthcare to Host First Quarter 2019 Financial Results and Business Update Conference Call on May 9, 2019

    BOCA RATON, Fla. , April 25, 2019 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological ...

  • Sensus Healthcare Signs R&D Agreement to Collaborate with Perelman School of Medicine at the University of Pennsylvania on World's First Sculptura™ Intraoperative Radiation Therapy System
    PR Newswire2 days ago

    Sensus Healthcare Signs R&D Agreement to Collaborate with Perelman School of Medicine at the University of Pennsylvania on World's First Sculptura™ Intraoperative Radiation Therapy System

    BOCA RATON, Fla., April 24, 2019 /PRNewswire/ -- Sensus Healthcare, Inc. (SRTS), a medical device company specializing in novel radiation oncology technologies and solutions, today announced that the Company has signed a research and development agreement with the Perelman School of Medicine at the University of Pennsylvania to collaborate with the radiation oncology department on clinical research and development for Sensus' Sculptura™ robotic intraoperative radiation therapy (IORT) system.

  • Five-Year Retrospective Study Shows 98.9 Percent Cure Rate for Non-Melanoma Skin Cancer Patients Treated with Sensus Healthcare's Superficial Radiation Therapy
    PR Newswire3 days ago

    Five-Year Retrospective Study Shows 98.9 Percent Cure Rate for Non-Melanoma Skin Cancer Patients Treated with Sensus Healthcare's Superficial Radiation Therapy

    BOCA RATON, Fla., April 23, 2019 /PRNewswire/ -- Sensus Healthcare, Inc. (SRTS), a medical device company specializing in non-invasive treatments for both oncological and non-oncological conditions, announced today topline results from a five-year retrospective study of non-melanoma skin cancer (NMSC) patients treated with Superficial Radiation Therapy (SRT) (ClinicalTrials.gov Identifier: NCT03693937).

  • PR Newswirelast month

    Sensus Healthcare to Present at the 31st Annual ROTH Conference

    BOCA RATON, Fla. , March 13, 2019 /PRNewswire/ --  Sensus Healthcare, Inc.  (NASDAQ: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological ...

  • Sensus Healthcare Launches SRT University, an Online Portal to Support Physicians
    PR Newswirelast month

    Sensus Healthcare Launches SRT University, an Online Portal to Support Physicians

    BOCA RATON, Fla., March 12, 2019 /PRNewswire/ -- Sensus Healthcare, Inc. (SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announced today the launch of SRT University, an online portal to support physicians using Sensus devices and technology. The new online portal provides physicians and their staff access to Sensus' depository of information related to superficial radiation therapy (SRT) and intraoperative radiotherapy (IORT). "As we expand our course catalog, we strive to provide our physicians access to tools and educational materials that benefit their practice and positively effect patient outcomes," said Kal Fishman, Sensus Healthcare Chief Technology Officer.

  • Sensus Healthcare Appoints Dr. Ziv Karni as Chief Scientific Officer
    PR Newswire2 months ago

    Sensus Healthcare Appoints Dr. Ziv Karni as Chief Scientific Officer

    BOCA RATON, Fla., Feb. 28, 2019 /PRNewswire/ -- Sensus Healthcare, Inc. (SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announced today that the Company has appointed Dr. Ziv Karni to the role of Chief Scientific Officer, effective immediately. Dr. Karni, a pioneer in medical technology research and development, has more than 30 years of experience in the development and sales of medical and aesthetic technologies.

  • PR Newswire2 months ago

    U.S. FDA Grants Market Clearance to Sensus Healthcare's New Sculptura™ Radiation Oncology System

    BOCA RATON, Fla., Feb. 26, 2019 /PRNewswire/ -- Sensus Healthcare, Inc. (SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announced today that the U.S. Food and Drug Administration (FDA) has granted market clearance for the Company's groundbreaking Sculptura™ radiation oncology system. A single treatment during surgery, Sculptura™ can provide cancer patients and physicians a single radiation treatment at the point of surgery. "With the creation of Sculptura™, Sensus is pioneering a new whole approach to radiation oncology that will ultimately benefit both patients and the medical community at large," said Joe Sardano, Sensus Healthcare CEO.

  • PR Newswire2 months ago

    Sensus Healthcare Fourth Quarter Financial Results Feature Record Revenue and Continued Double-digit Growth

    Shipped 27 systems during the quarter including 15 SRT-100 Vision™ systems Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla. , Feb. 14, 2019 /PRNewswire/ --  Sensus Healthcare, Inc. ...

  • Leading Dermatologists Develop Consensus Guidelines for the Use of Superficial Radiation Therapy to Treat Non-Melanoma Skin Cancers and Keloids
    PR Newswire2 months ago

    Leading Dermatologists Develop Consensus Guidelines for the Use of Superficial Radiation Therapy to Treat Non-Melanoma Skin Cancers and Keloids

    Published in The Journal of Clinical and Aesthetic Dermatology, Consensus was Reached that SRT is Safe, and Effective in Treating SCC and BCC and Should be Considered as the First-Line Form of Radiation Treatment.

  • Cure Rate Exceeds 97 Percent in Retrospective Study of Sensus Healthcare's SRT-100™ for Treating Basal and Squamous Cell Carcinomas of the Lower Extremities
    PR Newswire2 months ago

    Cure Rate Exceeds 97 Percent in Retrospective Study of Sensus Healthcare's SRT-100™ for Treating Basal and Squamous Cell Carcinomas of the Lower Extremities

    BOCA RATON, Fla., Feb. 12, 2019 /PRNewswire/ -- Sensus Healthcare, Inc. (SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), announces the publication of a new retrospective study that showed a high cure rate exceeding 97 percent among older patients (mean age: 82.5 years) being treated for basal and squamous cell carcinomas on their lower extremities with Sensus' SRT-100TM Superficial Radiation Therapy.

  • PR Newswire3 months ago

    Sensus Healthcare to Host Fourth Quarter and Full Year 2018 Financial Results and Business Update Conference Call on February 14, 2019

    BOCA RATON, Fla. , Jan. 30, 2019 /PRNewswire/ --  Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with ...

  • PR Newswire5 months ago

    Sensus Healthcare Announces Low 3% Keloid Recurrence in Multicenter Case Series of 297 Patients Treated with Superficial Radiation Therapy

    BOCA RATON, Fla., Dec. 6, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), announced today positive results of a multicenter case series of patients treated with the SRT-100™ following complete surgical keloidectomy. Of the 297 keloidectomy patients treated post-operatively with superficial radiation, there were only nine cases of observed clinical keloid recurrences, or a recurrence rate of 3%.

  • Sensus Healthcare Installs First Groundbreaking SRT-100+ Superficial Radiation Therapy System for Treating Keloid Scars
    PR Newswire5 months ago

    Sensus Healthcare Installs First Groundbreaking SRT-100+ Superficial Radiation Therapy System for Treating Keloid Scars

    BOCA RATON, Fla., Nov. 29, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), has installed its first SRT-100+ system at Hillcrest Plastic Surgery in Orlando, Fla., specifically for the treatment of keloid scars. Earlier this year, Sensus received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its new SRT-100+, which adds several innovative features to Sensus' existing SRT-100 product for non-melanoma skin cancer and keloid treatment.

  • GlobeNewswire5 months ago

    Report: Exploring Fundamental Drivers Behind Affimed N.V, Sensus Healthcare, Lifetime Brands, SigmaTron International, Salem Media Group, and Origin Agritech — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Nov. 15, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • PR Newswire6 months ago

    Sensus Healthcare Third Quarter Financial Results Feature Revenue Growth of 32%

    Shipped 18 systems during the quarter including 15 SRT-100 Vision™ systems Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla. , Nov. 1, 2018 /PRNewswire/ --  Sensus Healthcare, Inc. ...

  • PR Newswire6 months ago

    Sensus Healthcare to Host Third Quarter 2018 Financial Results and Business Update Conference Call on November 1, 2018

    BOCA RATON, Fla. , Oct. 22, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS),   a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with ...

  • PR Newswire6 months ago

    Sensus Healthcare Brings Groundbreaking SRT-100 Vision System to Israel's Largest Hospital for Skin Cancer and Keloid Treatment

    BOCA RATON, Fla., Oct. 17, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), today announced that the Company has shipped  its third SRT-100 Vision™ system to Israel, with the newest unit located at the Sheba Medical Center in Tel HaShomer, near Tel Aviv. The other two previously installed units reside at the Ichilov Hospital in Tel Aviv and Beilinson Hospital / Rabin Medical Center in Petah Tikva.

  • PR Newswire6 months ago

    South Florida Business Journal Recognizes Sensus Healthcare's Chief Technology Officer at 2018 Technology Awards

    BOCA RATON, Fla., Oct. 16, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), today announced that the South Florida Business Journal has recognized the Company's Chief Technology Officer, Kal Fishman, as a finalist at this year's Technology Awards. "For nearly a decade, Kal has played an incredibly instrumental role in Sensus Healthcare's overarching success, and his vast accomplishments continue to be recognized each year, both locally and globally," said Joe Sardano, CEO of Sensus Healthcare.

  • PR Newswire7 months ago

    Sensus Healthcare, Inc. Announces Underwriters' Exercise of Option

    BOCA RATON, Fla., Sept. 21, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (SRTS) announced today that it has issued an additional 330,882 shares of its common stock pursuant to the exercise in full of the underwriters' option received in connection with Sensus' recently completed public offering of its common stock. After giving effect to the full exercise of the option, Sensus sold an aggregate of 2,536,764 shares of its common stock at a price of $6.80 per share with total gross proceeds of approximately $17.25 million, before deducting underwriting discounts and commissions and other estimated offering expenses. B. Riley FBR acted as the lead underwriter and sole book-running manager for the offering.

  • Sensus Healthcare, Inc. Announces Closing of Public Offering of Common Stock
    PR Newswire7 months ago

    Sensus Healthcare, Inc. Announces Closing of Public Offering of Common Stock

    BOCA RATON, Fla., Sept. 17, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (SRTS) announced today that it completed a public offering of 2,205,882 shares of its common stock, par value $0.01 per share, at a public offering price of $6.80 per share. The shares are listed on The Nasdaq Capital Market under the ticker symbol "SRTS."  Total proceeds to Sensus from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $15 million. Sensus has granted the underwriters a 30-day option to purchase up to an additional 330,882 shares at the public offering price, less underwriting discounts and commissions. B. Riley FBR acted as the lead underwriter and sole book-running manager for the offering.

  • Sensus Healthcare, Inc. Announces Pricing of Public Offering of Common Stock
    PR Newswire7 months ago

    Sensus Healthcare, Inc. Announces Pricing of Public Offering of Common Stock

    BOCA RATON, Fla., Sept. 13, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (SRTS) announced today that it has priced an underwritten public offering of 2,205,882 shares of its common stock, par value $0.01 per share, at a public offering price of $6.80 per share. Sensus has granted a 30-day option to purchase up to an additional 330,882 shares pursuant to the underwriting agreement. The gross proceeds to the Company from this offering are expected to be approximately $15 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.

  • PR Newswire7 months ago

    Sensus Healthcare, Inc. Announces Commencement of Public Offering of Common Stock

    BOCA RATON, Fla., Sept. 12, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (SRTS) announced today that it commenced a public offering of its common stock, par value $0.01 per share. In addition, Sensus intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the public offering. The offering will be made only by means of a prospectus supplement and an accompanying prospectus filed as part of an effective shelf registration statement filed with the Securities and Exchange Commission on Form S-3.

  • PR Newswire8 months ago

    Sensus Healthcare Presents at National Cancer Care Alliance Leadership Board and Practice Quarterly Meeting

    BOCA RATON, Fla., Sept. 7, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), today announced that Joe Sardano, President and Chief Executive Officer, participated at the National Cancer Care Alliance (NCCA) Leadership Board and Practice Quarterly Meeting, which took place Thursday, August 30 through Friday, August 31, 2018, in Chicago. "At this pivotal point in Sensus' acceleration as an international provider of solutions for non-invasive skin cancer treatment, it is an honor to address the NCCA at the invitation of founder and current chair of the board Dr. Barbara McAneny," Sardano said.

  • PR Newswire8 months ago

    Sensus Healthcare to Participate in Two Upcoming Investor Conferences

    BOCA RATON, Fla. , Aug. 27, 2018 /PRNewswire/ --  Sensus Healthcare, Inc. (Nasdaq: SRTS ), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with ...

  • CNW Group8 months ago

    Sensus Healthcare CEO Joseph C. Sardano Joins BirchBioMed Inc. Board of Directors

    VANCOUVER , Aug. 13, 2018 /CNW/ - BirchBioMed Inc., a clinical-stage biomedical company focused on the clinical evaluation, development and commercialization of anti-scarring drugs, autoimmune therapeutics and novel strategies for transplantation, today announced the appointment of Joseph C. Sardano to its board of directors. A recognized leader in the healthcare industry, Mr. Sardano is Chairman of the Board, President and CEO of Sensus Healthcare, Inc. (SRTS), which specializes in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT). Mr. Sardano's appointment as BirchBioMed's first independent director is effective immediately.